文献速递临床免疫临床微生物

新型BioPlex莱姆病血清学检测在欧洲莱姆病患者中的诊断性能

Diagnostic Performance of the Novel BioPlex Lyme Serological Assays in European Patients with Lyme Disease.
PubMed 文献 · J Clin Microbiol · 2021-06-18

本研究评估了新型BioPlex 2200莱姆IgG和IgM检测对158例荷兰确诊莱姆病患者的敏感性和特异性,并与两种商业酶免疫检测及一种免疫印迹比较。BioPlex在早期莱姆病中敏感性最高(92.1%),但健康献血者中特异性较低(71.4%),经临界值优化后特异性可提高至89.3%。

要点

  • BioPlex在早期莱姆病中敏感性达92.1%,优于Euroimmun和C6-ELISA。
  • BioPlex在健康献血者中特异性为71.4%,低于两种ELISA。
  • 基于ROC分析优化的BioPlex版本可保持高敏感性并提高特异性。

核心结论

  • BioPlex 2200莱姆IgG和IgM检测是早期莱姆病血清学诊断的有前景工具,有潜力作为独立检测使用。

研究设计与样本

  • 研究纳入158例荷兰医生确诊的莱姆病患者(包括早期局限性和播散性)、800名荷兰健康献血者和90例交叉反应对照。
  • 将BioPlex检测与两种商业酶免疫检测(Euroimmun和C6-ELISA)及一种免疫印迹(recomLine)进行比较。
  • 通过受试者工作特征(ROC)分析评估检测的潜在改进。

主要发现

  • 早期莱姆病中BioPlex敏感性最高(81/88,92.1%),Euroimmun为64/88(72.7%),C6-ELISA为72/88(81.8%)。
  • 播散性莱姆病患者中所有检测的敏感性相当。
  • 健康献血者中BioPlex特异性为571/800(71.4%),Euroimmun为711/800(88.9%),C6-ELISA为727/800(90.9%)。
  • ROC分析显示联合BioPlex IgG和IgM检测的6种抗原中有2种具有显著更高的曲线下面积(AUC)。
  • 基于这些抗原的潜在改良版本在EM患者中敏感性为81/80(92.1%),特异性为714/800(89.3%)。

关键数值与推荐

  • 早期莱姆病敏感性:BioPlex 81/88(92.1%),Euroimmun 64/88(72.7%),C6-ELISA 72/88(81.8%)。
  • 健康献血者特异性:BioPlex 571/800(71.4%),Euroimmun 711/800(88.9%),C6-ELISA 727/800(90.9%)。
  • 改良BioPlex版本在EM患者中敏感性81/80(92.1%),特异性714/800(89.3%)。

临床怎么用

  • BioPlex检测可用于早期莱姆病的血清学诊断,敏感性优于现有ELISA。
  • 在特异性要求高的场景中,需注意BioPlex的假阳性风险,可考虑临界值优化。

局限性

  • 研究为发现队列,需进一步研究验证结果。
  • 特异性评估基于健康献血者,可能不反映真实临床人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serodiagnosis of Lyme borreliosis (LB) comes with several drawbacks, among which is limited sensitivity in early disease. This study assesses the sensitivity and specificity of the novel BioPlex 2200 Lyme IgG and Lyme IgM assays. It also assesses potential improvements to the assays through receiver-operating characteristic (ROC) analysis. The BioPlex assays were performed on sera of 158 Dutch patients with physician-confirmed LB (both early localized and disseminated), 800 healthy blood donors from the Netherlands, and 90 cross-reactive controls. The BioPlex (Biopl) assays were compared with two commercial enzyme immunoassays (Euroimmun [Eur]/C6-ELISA) and one immunoblot (recomLine). The highest sensitivity in early LB was achieved with the BioPlex assays, which outperformed the Euroimmun and C6-ELISA (Biopl: 81/88, 92.1%; Eur: 64/88, 72.7%; C6: 72/88, 81.8%). Sensitivity of all assays was comparable in patients with disseminated LB. The BioPlex assays were outperformed in terms of specificity (all healthy blood donors, Biopl: 571/800, 71.4%; Eur: 711/800, 88.9%; C6: 727/800, 90.9%), but further analyses showed promising avenues following cutoff optimization. ROC analysis showed that 2/6 antigens of the combined BioPlex IgG and IgM assays had significantly higher areas under the curve (AUCs) than those of the other analyses. Potential modified versions of the assays based on these antigens largely outperformed the Euroimmun and C6-ELISA in EM patients (Biopl: 81/80, 92.1%) while maintaining a comparable or even higher specificity (Biopl: 714/800, 89.3%). The BioPlex 2200 Lyme IgG and Lyme IgM assays are promising tools for the serodiagnosis of early LB, with the potential to be used as a standalone test. Further research is necessary to validate the findings of this discovery cohort.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Baarsma ME, Ursinus J, Zaaijer HL, et al. Diagnostic Performance of the Novel BioPlex Lyme Serological Assays in European Patients with Lyme Disease. J Clin Microbiol. 2021. PMID: 33883179. doi:10.1128/JCM.03205-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。